Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,481 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial.
Tomizawa D, Miyamura T, Imamura T, Watanabe T, Moriya Saito A, Ogawa A, Takahashi Y, Hirayama M, Taki T, Deguchi T, Hori T, Sanada M, Ohmori S, Haba M, Iguchi A, Arakawa Y, Koga Y, Manabe A, Horibe K, Ishii E, Koh K. Tomizawa D, et al. Among authors: takahashi y. Blood. 2020 Oct 15;136(16):1813-1823. doi: 10.1182/blood.2019004741. Blood. 2020. PMID: 32845001 Free article.
Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group.
Nagayama J, Tomizawa D, Koh K, Nagatoshi Y, Hotta N, Kishimoto T, Takahashi Y, Kuno T, Sugita K, Sato T, Kato K, Ogawa A, Nakahata T, Mizutani S, Horibe K, Ishii E; Japan Infant Leukemia Study Group. Nagayama J, et al. Among authors: takahashi y. Blood. 2006 Jun 15;107(12):4663-5. doi: 10.1182/blood-2005-11-4728. Epub 2006 Feb 14. Blood. 2006. PMID: 16478880 Free article. Clinical Trial.
Gene alterations involving the CRLF2-JAK pathway and recurrent gene deletions in Down syndrome-associated acute lymphoblastic leukemia in Japan.
Hanada I, Terui K, Ikeda F, Toki T, Kanezaki R, Sato T, Kamio T, Kudo K, Sasaki S, Takahashi Y, Hayashi Y, Inukai T, Kojima S, Koike K, Kosaka Y, Kobayashi M, Imaizumi M, Mitsui T, Hori H, Hara J, Horibe K, Nagai J, Goto H, Ito E. Hanada I, et al. Among authors: takahashi y. Genes Chromosomes Cancer. 2014 Nov;53(11):902-10. doi: 10.1002/gcc.22201. Epub 2014 Jul 16. Genes Chromosomes Cancer. 2014. PMID: 25044358
Protracted Administration of L-Asparaginase in Maintenance Phase Is the Risk Factor for Hyperglycemia in Older Patients with Pediatric Acute Lymphoblastic Leukemia.
Yoshida H, Imamura T, Saito AM, Takahashi Y, Suenobu S, Hasegawa D, Deguchi T, Hashii Y, Kawasaki H, Endo M, Hori H, Suzuki N, Kosaka Y, Kato K, Yumura-Yagi K, Hara J, Oda M, Sato A, Horibe K; Japan Association of Childhood Leukemia Study. Yoshida H, et al. Among authors: takahashi y. PLoS One. 2015 Aug 28;10(8):e0136428. doi: 10.1371/journal.pone.0136428. eCollection 2015. PLoS One. 2015. PMID: 26317422 Free PMC article. Clinical Trial.
Low Incidence of Osteonecrosis in Childhood Acute Lymphoblastic Leukemia Treated With ALL-97 and ALL-02 Study of Japan Association of Childhood Leukemia Study Group.
Sakamoto K, Imamura T, Kihira K, Suzuki K, Ishida H, Morita H, Kanno M, Mori T, Hiramatsu H, Matsubara K, Terui K, Takahashi Y, Suenobu SI, Hasegawa D, Kosaka Y, Kato K, Moriya-Saito A, Sato A, Kawasaki H, Yumura-Yagi K, Hara J, Hori H, Horibe K. Sakamoto K, et al. Among authors: takahashi y. J Clin Oncol. 2018 Mar 20;36(9):900-907. doi: 10.1200/JCO.2017.75.5066. Epub 2018 Jan 23. J Clin Oncol. 2018. PMID: 29360413
Discontinuation of L-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia.
Usami I, Imamura T, Takahashi Y, Suenobu SI, Hasegawa D, Hashii Y, Deguchi T, Hori T, Shimada A, Kato K, Ito E, Moriya-Saito A, Kawasaki H, Hori H, Yumura-Yagi K, Hara J, Sato A, Horibe K; Japan Association of Childhood Leukemia Study Group (JACLS). Usami I, et al. Among authors: takahashi y. Int J Hematol. 2019 Apr;109(4):477-482. doi: 10.1007/s12185-019-02599-w. Epub 2019 Jan 28. Int J Hematol. 2019. PMID: 30689137
Personalized pharmacokinetic targeting with busulfan in allogeneic hematopoietic stem cell transplantation in infants with acute lymphoblastic leukemia.
Takachi T, Arakawa Y, Nakamura H, Watanabe T, Aoki Y, Ohshima J, Takahashi Y, Hirayama M, Miyamura T, Sugita K, Koh K, Horibe K, Ishii E, Mizutani S, Tomizawa D. Takachi T, et al. Among authors: takahashi y. Int J Hematol. 2019 Sep;110(3):355-363. doi: 10.1007/s12185-019-02684-0. Epub 2019 Jun 14. Int J Hematol. 2019. PMID: 31201644 Clinical Trial.
Risk-adjusted therapy for pediatric non-T cell ALL improves outcomes for standard risk patients: results of JACLS ALL-02.
Hasegawa D, Imamura T, Yumura-Yagi K, Takahashi Y, Usami I, Suenobu SI, Nishimura S, Suzuki N, Hashii Y, Deguchi T, Moriya-Saito A, Kato K, Kosaka Y, Hirayama M, Iguchi A, Kawasaki H, Hori H, Sato A, Kudoh T, Nakahata T, Oda M, Hara J, Horibe K; Japan Association of Childhood Leukemia Study Group (JACLS). Hasegawa D, et al. Among authors: takahashi y. Blood Cancer J. 2020 Feb 27;10(2):23. doi: 10.1038/s41408-020-0287-4. Blood Cancer J. 2020. PMID: 32107374 Free PMC article. Clinical Trial.
12,481 results
You have reached the last available page of results. Please see the User Guide for more information.